Elevating Healthcare. Transforming Lives.®
Stay up to date with the latest pharmaceutical industry news and USA MedPremium updates.
If your clinic built a weight-loss or aesthetics program on compounded semaglutide or tirzepatide, the ground has shifted. A 2026 guide to the only defensible GLP-1 sourcing path after the compounding crackdown — what changed, the FDA-approved products, authorized-distributor buying, and the marketing claims that trigger enforcement.
“It shipped overnight” is the most expensive assumption in healthcare procurement — speed is not a cold chain. A 2026 guide to why peptides are temperature-sensitive, the USP and FDA-label standards that govern cold-chain handling, and exactly what to require of any supplier before you trust them with refrigerated inventory.
The price on a peptide invoice matters less than the legal framework behind it. A 2026 buyer’s guide to 503A vs. 503B compounding — what each authorizes, where peptides and GLP-1s fall today, the DSCSA exemption most teams miss, and a pre-sourcing due-diligence checklist.
The peptide compounding exemptions built on the 2024 GLP-1 shortages have expired, and FDA has shifted to coordinated enforcement against unapproved peptide channels. A 2026 guide to what changed, where the compliance exposure sits, and how to qualify a supply chain partner built to the standard your facility is held to.
The ACDS named benzyl alcohol the 2026 Allergen of the Year — and preservative-free IV solutions have shifted from specialty accommodation to mainstream procurement priority. A 2026 guide for hospital pharmacies, infusion centers, and 503B compounding on PF procurement strategy.
Your practice stocks the insulin — but does it stock the right pen needle gauge for every patient's device? A 2026 supply guide for medical practices, endocrinology clinics, infusion centers, and home health agencies: pen needle selection, ancillary consumables, DSCSA-compliant sourcing, and the procurement discipline that keeps diabetes care moving.
A procurement playbook for infusion centers and specialty pharmacies: how to source biologics, biosimilars, oncology injectables, IVIG, and specialty antibiotics when manufacturer allocation and API disruptions are the norm — with DSCSA-compliant sourcing and multi-manufacturer strategy.
Preservative-free famotidine and lanthanum carbonate (Fosrenol) are intermittently constrained through 2026. A procurement guide for facility buyers: shortage drivers, DSCSA compliance, 503B fallbacks, and multi-source GI drug sourcing.
The ceftriaxone shortage has extended into 2026 with no resolution in sight. A procurement guide for outpatient facilities on multi-manufacturer sourcing, antimicrobial stewardship, DSCSA-compliant vendor vetting, and substitution protocols that hold when the primary supplier is backordered.
With 270 active drug shortages and operating costs up 39%, dermatology procurement is now a clinical function. This guide covers the seven supply categories every practice needs, par level benchmarks, and sourcing strategies to keep your shelves stocked through 2026.
Your infusion components should work as a system. Learn how to choose IV administration sets, catheters, connectors, and bags that are compatible from bag to vein.
Estradiol patches remain on allocation through mid-2026. This guide covers alternative delivery forms, 503B compounding, dosing equivalence, and procurement strategies to keep patients on effective HRT.
